Trials / Completed
CompletedNCT01155817
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
A Phase 1 Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PRIMARY OBJECTIVES: Determine the safety and tolerability of nilotinib in steroid dependent / refractory cGVHD. SECONDARY OBJECTIVES: Determine the clinical efficacy of nilotinib in steroid dependent / refractory cGVHD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib | 200, 400, 800, oral |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2010-07-02
- Last updated
- 2020-04-15
Locations
5 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01155817. Inclusion in this directory is not an endorsement.